Trevi Therapeutics, Inc. TRVI

Trevi Therapeutics has delivered very strong long term gains, yet the stock now screens as expensive on broad valuation checks. This raises questions about how much of the story is already in the price. The stock has returned roughly 10x over the past 5 years, which is an unusually large move that can leave less room for valuation mistakes. Upcoming presentations in 2026 on nalbuphine ER trial data may support confidence in the Trevi Therapeutics pipeline. Any disappointment in clinical...

NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will participate in the following conferences in September. 2026 Cantor Global He

Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough Dr. Imran Satia will give a poster presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2a RIVER trial of nalbuphine ER for the treatment of patients with RCC NEW HAVEN, Conn., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a

Trevi Therapeutics Inc (TRVI) reports progress in IPF and RCC trials, backed by $319 million in funding and a competitive edge following a rival's program exit.

Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026 Initiated Phase 2b LAKE trial for patients with refractory chronic cough in the second quarter; sample size re-estimation expected in the fourth quarter of 2026 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics,

Conference call and webcast to be held at 4:30 p.m. ETNEW HAVEN, Conn., July 30, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call

NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will participate in the following conferences in August. Oppenheimer's Biotech in

Trevi Therapeutics grew its share prices by 9.85 percent on Friday to finish at $19.07 apiece, after management underscored strong clinical trial results from its treatment candidate for chronic cough. Speaking at a three-day conference in Europe, Trevi Therapeutics Inc (NASDAQ:TRVI) CEO Jennifer Good and Chief Development Officer James Cassella highlighted that the oral treatment […]

NEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will attend several upcoming events in June and July. BIO International Convention

Moby summary of Trevi Therapeutics, Inc.'s Q1 2026 earnings call

Trevi Therapeutics recently reported a first‑quarter 2026 net loss of US$13.19 million, broadly flat on a per‑share basis, while outlining plans to advance multiple chronic cough trials for its lead drug Haduvio. Alongside this, the company raised approximately US$162 million in a follow‑on offering, extending its cash runway into 2030 and supporting expanded clinical development and intellectual property efforts. We’ll now examine how the extended cash runway to 2030 reshapes Trevi’s...

Trevi Therapeutics (NASDAQ:TRVI) management used the company’s first-quarter 2026 earnings call to outline upcoming clinical milestones for its chronic cough programs and to highlight an expanded cash runway following an April equity offering. Clinical program updates and upcoming trial starts Pres